SANOFI is currently recruiting volunteers for a clinical research study involving their investigational product, Dupilumab, in severe asthma for patients who are taking oral corticosteroids (like prednisone) daily.

The purpose of the study is to determine if patients who take Dupilumab are more able to either reduce or discontinue the use of the oral corticosteroids compared to those who take placebo (but remain on their current treatments at the same time).

Dupilumab is a monoclonal antibody type product which requires it be injected under the skin every 2 weeks. The study treatment period is 6 months and patients who complete the study will have the opportunity to join an open label extension study (where all patients get Dupilumab).

 More detailed information can be obtained by going to and/or to and using the search code NCT0252821.